# Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Source: https://onco.cc/trials/nct04821622/  
OnCo record `nct04821622` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Talazoparib and Enzalutamide in prostate cancer, run by Pfizer, active and no longer recruiting.

## Summary

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC is a phase 3 interventional study registered as NCT04821622 by Pfizer, with 599 participants enrolled, started 2021-05-12 and due to reach its primary completion in 2026-02-18. Interventions recorded: talazoparib plus enzalutamide and Placebo plus enzalutamide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04821622
- Phase: 3
- Setting: TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
- Sponsor: Pfizer
- Enrolled: 599

## Sources

- ClinicalTrials.gov NCT04821622: https://clinicaltrials.gov/study/NCT04821622

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Talazoparib](https://onco.cc/drugs/talazoparib/)
- companies: [Astellas](https://onco.cc/companies/astellas/), [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct04821622.json